Inclusion Criteria:

          -  Each patient must be positive for HLA-A*02 and meet all of the following inclusion
             criteria to be enrolled in the study:

          -  Histologically or cytologically proven HPVOC or cervical cancer or anal cancer, based
             on expression of HPV type16 in immunohistochemistry and/or HPV 16 DNA analysis by ISH
             of tumor tissue from the primary or metastatic lesions.

          -  Incurable HPVOC, as defined by:

               -  Relapsed or progressive disease at the primary site and/or regional lymph nodes
                  after initial treatment (e.g. Surgery, radiotherapy or chemoradiotherapy) with no
                  potentially curative option (i.e. surgery or radiation); OR

               -  Distant metastasis

          -  Incurable cervical or anal cancer, as defined by:

               -  Relapsed or progressive disease at the primary site and/or regional lymph nodes
                  after initial treatment (e.g. systemic chemotherapy) with no potentially curative
                  option (i.e. surgery or chemoradiotherapy). Chemotherapy administered in
                  conjunction with primary radiation as a radiosensitizer will not be counted as a
                  systemic chemotherapy regimen; OR

               -  Distant metastasis refractory to initial treatment (at least one prior
                  chemotherapeutic regimen which can include a single chemotherapeutic, a
                  combination of chemotherapeutics, or biologic drugs such as bevacizumab).

          -  Accessible tumors for sequential biopsies Terminology Criteria for Adverse Events
             Version 4.0 (CTCAE v4.03) to grade 1 or better (except for < grade 2 neuropathy,
             alopecia, xerostomia, dysphagia, or mucositis);

          -  Age ≥ 18 years;

          -  Measurable disease, according to modified RECIST 1.1 and irRECIST (Appendix B & C);

          -  Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2 (Appendix A)

          -  Adequate bone marrow, liver and renal function, defined by:

               -  Hemoglobin ≥ 10 g/dL;

               -  Absolute neutrophil count (ANC) ≥ 1000/μL;

               -  Absolute lymphocyte count ≥ 400/μL;

               -  Platelet count ≥ 100,000/μL;

               -  ALT and AST ≤ 2.5 X upper limit of normal (ULN);

               -  Total bilirubin ≤ 1.5 X ULN; and

               -  Serum creatinine ≤ 1.5 X ULN;

          -  Women of child-bearing potential (WOCBP) must be willing to use acceptable means of
             birth control;

          -  Men who could potentially father a child must also use birth control

          -  Signed informed consent

        Exclusion Criteria:

          -  Radiotherapy for primary HPVOC within 8 weeks, or radiotherapy for any other reason
             within 3 weeks prior to the first dose of trial treatment;

          -  Chemotherapy within 3 weeks prior to the first dose of trial treatment;Other cancer in
             the past 5 years, except for carcinoma in situ of the cervix or bladder, or
             non-melanomatous skin cancer;

          -  Inaccessible tumor or lack of consent for sequential biopsies

          -  Uncontrolled central nervous system (CNS) metastases (i.e. known CNS lesions that are
             radiographically unstable, symptomatic and/or requiring escalating doses of
             corticosteroids);

          -  Active hepatitis, known HIV, or other condition that requires immunosuppressive
             therapy, including current use of high dose systemic corticosteroids;

          -  Autoimmune disease, such as systemic lupus erythematosis or rheumatoid arthritis, that
             is active and requires current immunosuppressive therapy;

          -  Active uncontrolled serious infection;

          -  WOCBP who have a positive β-hCG test or are breastfeeding.

          -  Acute or chronic skin disorders that would interfere with subcutaneous injection of
             the vaccine or subsequent assessment of potential skin reactions;

          -  Allergies to any vaccine, that after discussion with Immunovaccine, are serious enough
             to warrant exclusion from this study